Vinnie, Vin Milano became the CEO of Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) in 2014. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. After that, we will consider the growth in the business. Third, we’ll reflect on the total return to shareholders over three years, as a second measure of business performance. This process should give us an idea about how appropriately the CEO is paid.

View our latest analysis for Idera Pharmaceuticals

Want to help shape the future of investing tools and platforms? Take the survey and be part of one of the most advanced studies of stock market investors to date.

How Does Vinnie, Vin Milano’s Compensation Compare With Similar Sized Companies?

Our data indicates that Idera Pharmaceuticals, Inc. is worth US$99m, and total annual CEO compensation is US$1.2m. (This is based on the year to 2017). While this analysis focuses on total compensation, it’s worth noting the salary is lower, valued at US$600k. We examined a group of similar sized companies, with market capitalizations of below US$200m. The median CEO compensation in that group is US$303k.

It would therefore appear that Idera Pharmaceuticals, Inc. pays Vinnie, Vin Milano more than the median CEO remuneration at companies of a similar size, in the same market. However, this fact alone doesn’t mean the remuneration is too high. We can get a better idea of how generous the pay is by looking at the performance of the underlying business.

You can see a visual representation of the CEO compensation at Idera Pharmaceuticals, below.

Is Idera Pharmaceuticals, Inc. Growing?

On average over the last three years, Idera Pharmaceuticals, Inc. has grown earnings per share (EPS) by 7.6% each year (using a line of best fit). In the last year, its revenue is down -95%.

I generally like to see a little revenue growth, but the improvement in EPS is good. In conclusion we can’t form a strong opinion about business performance yet; but it’s one worth watching.

It could be important to check this free visual depiction of what analysts expect for the future.

Has Idera Pharmaceuticals, Inc. Been A Good Investment?

With a three year total loss of 79%, Idera Pharmaceuticals, Inc. would certainly have some dissatisfied shareholders. This suggests it would be unwise for the company to pay the CEO too generously.

In Summary…

We compared the total CEO remuneration paid by Idera Pharmaceuticals, Inc., and compared it to remuneration at a group of similar sized companies. We found that it pays well over the median amount paid in the benchmark group.